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esomeprazole. METHODS: The number of patients with GERD
was derived from epidemiological studies. The number of proton
pump inhibitor (PPI) users was calculated from IMS publications
and reimbursement data provided by sick-funds. According to
clinical practice, in future, the number of patients taking a PPI
will be the number of weekly GERD sufferers. Alternatively,
future PPI users will comprise patients currently receiving a PPI
plus those currently using H2-receptor antagonists, plus a large
part of current antacids users. Results of on-demand treatment
come from the ONE study (2-arm parallel study over a 6-month
maintenance period, on-demand versus continuous therapy with
esomeprazole 20mg). RESULTS: A totla of 28% of the Belgian
adult population (n = 10 million) have GERD symptom(s), 11%
weekly, 4% daily. Assuming stable prevalence of GERD over the
next decade, the number of PPI-treated patients could reach
approximately 920,000/year from 446,000 currently. Yearly
expenses would therefore increase from 149€ to 248€ million.
This would be reached by 2010 with linear growth or 2005 with
exponential growth. In 2652 Belgian patients with a similar
proﬁle to the screened population of the epidemiological studies,
the ONE study showed on-demand treatment (mean daily
intake: 0.6 tablet) was similar to continuous treatment (1
tablet/day) for patient satisfaction (92% in both groups), heart-
burn relapse (11.3% vs. 9.4%, respectively) and GERD-related
co-medication intake (8% vs. 7.3%, respectively). Over a 7-
month treatment period (4 weeks of acute treatment then 6
months’ maintenance), on-demand esomeprazole 20mg would
save approximately 27.5% on medication costs compared with
continuous esomeprazole therapy. CONCLUSIONS: Increasing
costs due to the expected increased use of PPI’s can be lowered
by using an effective PPI with an on-demand approach, which
maintains high patient satisfaction and efﬁcacy.
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OBJECTIVES: Gastro Esophageal Reﬂux Disease (GERD) is a
chronic condition that may affect patients’ quality of life. It is
one of the most common complaints in primary care settings
with relevant consequences on health economics in terms of
increasing health costs and limiting resources. An objective 
of this multicentre trial was to evaluate the time of action of
rabeprazole 20mg daily (RAB) and omeprazole 20mg daily
(OME) in inducing symptom relief in patients with reﬂux
oesophagitis in the curative phase. A prospective health eco-
nomic analysis was performed to compare the costs of the 2
treatments in obtaining symptoms improvement. METHODS: A
total of 484 patients, with mild to severe reﬂux oesophagitis
(Savary-Miller grade I to III), were randomised in a double-blind,
parallel group fashion, to receive RAB or OME for a period of
4 to 8 weeks with control visits every two weeks. The patients
had to ﬁll in a daily diary regarding to the number of tablets/cap-
sules taken, and the daytime and night time heartburn intensity
using the following score: absent, mild, moderate, severe and ter-
rible. The economic analysis was designed and carried out from
a societal and National Health Service perspective. RESULTS: In
the curative phase of reﬂux oesophagitis (4–8 weeks) treatment
with RAB (20mg) resulted less expensive than OME (20mg).
The estimated mean total costs were found to be lower in RAB
group (58.04€) than in the OME one (64.34€; p < 0.001). With
regard to numbers of symptom-free days, RAB (67.1%) was
found to be more effective than OME (66.8%). CONCLU-
SIONS: Rabeprazole (20mg) once daily is cost effective com-
pared with omeprazole (20mg) once daily in the curative phase
of reﬂux oesophagitis. Rabeprazole represents good value for
money and efﬁcient use of health care resources in the treatment
of reﬂux oesophagitis.
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OBJECTIVES: Endoscopic and laparoscopic surgeries are now
widely used to treat patients with stones in gallbladder and
common bile duct (CBD). The objectives of this study were to
compare the economic and clinical results between two methods
in the treatment of stones in gallbladder and CBD. METHODS:
A computer model was established to assess the cost-beneﬁt of
two types of treatment from the provider’s perspective. Treat-
ment A provided two-stage procedure, which performs endo-
scopic sphincterotomy (EST) ﬁrst and then followed by
laparoscopic cholecystectomy (LC) (EST + LC). Treatment B is
a one-stage procedure that performs laparoscopic surgery alone
to remove both the gallbladder and stones in common bile duct
(LCBDE + LC). Sources of parameters for the simulation model
came from the results of published articles and patients received
endoscopic and/or laparoscopic surgery in a medical center.
RESULTS: Treatment B had a better successful rate than that of
treatment A and a shorter length of hospital stay. However, treat-
ment A had better stone removal rate. Under current insurance
payment schedule, the net beneﬁt of treatment A is NT$ 16,816
and NT$ -11,603 for treatment B. Therefore, it will be cost-ben-
eﬁcial to do EST + LC under current payment schedule. Sensi-
tivity analysis showed that hospitals must reduce the cost of
LCBDE + LC to NT$ 44,500 to avoid loss (currently NT$
85,513). If the cost of LCBDE + LC can be reduced to 33,000,
it can achieve the same beneﬁt as EST + LC. CONCLUSIONS:
Providers should hold the therapy of EST + LC to be the major
treatment under current insurance payment schedule. LCBDE +
LC is not commonly performed in Taiwan because of insufﬁcient
payment. However, it has the advantage of reducing patients’
suffering, shorter operation waiting time, and shorter hospital
stay. It would be beneﬁcial to patients if hospitals can reduce the
cost of LCBDE + LC and perform the procedure when appro-
priate.
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OBJECTIVES: There have been only a few studies published in
the world literature to date dealing with the pharmacoeconom-
ics of Crohnxs disease including east and central European coun-
tries. METHODS: The retrospective cost of illness study was
carried out by the analysis of all medical records and by special
questionnaire of patients suffering from Crohnxs disease in
1999–2000. RESULTS: Of 54 patients, 30 women, and 24 men,
with the average age of 48.8 years and with the average dura-
tion of illness of 75.8 months, were divided into 3 subgroups
from the point of view of pharmacoeconomics: A,—uncompli-
cated, 24 persons, B,—with chronic corticosteroid treatment, 12
